L-carvone is the spearmint-leaning enantiomer of carvone and one of the clearest aroma markers in spearmint oil. The strongest live evidence for this specific form is identity, odor character, human metabolism, TRPV1-related sensory pharmacology, and contact-allergy relevance rather than clinical efficacy. For AromaForge, it is most accurate to position l-carvone as a high-recognition mint ketone with meaningful sensory and fragrance-safety literature, while keeping any benefit language non-medical and noting that much of the bioactivity work remains preclinical.
Chemical identity and composition
PubChem assigns the specific l-carvone record to the (-)-/(5R) enantiomer, while JECFA separately describes l-carvone as the spearmint-like form. In the archive, spearmint oil records already distinguish `l_carvone` from generic parent `carvone`, which matters because odor description and some literature are enantiomer-specific.
Aroma and practical use
- Use the recorded spearmint-like, minty, sweet, fresh, herbal, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2013 study reported that (-)-carvone increased cytosolic calcium in dorsal root ganglion neurons and showed dose-dependent activity in human TRPV1-expressing cells, with an EC50 of about 1.3 mM in the HEK293 model.
A 2013 study reported that (-)-carvone increased cytosolic calcium in dorsal root ganglion neurons and showed dose-dependent activity in human TRPV1-expressing cells, with an EC50 of about 1.3 mM in the HEK293 model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2001 human metabolism study found no major qualitative metabolism difference between S-(+)- and R-(-)-carvone and identified dihydrocarvonic acid, carvonic acid, and uroterpenolone as the major in vivo metabolites.
A 2001 human metabolism study found no major qualitative metabolism difference between S-(+)- and R-(-)-carvone and identified dihydrocarvonic acid, carvonic acid, and uroterpenolone as the major in vivo metabolites.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A North American Contact Dermatitis Group analysis found 188 positive reactions among 24,124 patients tested to carvone, supporting real-world allergy relevance even though positivity remained uncommon overall.
A North American Contact Dermatitis Group analysis found 188 positive reactions among 24,124 patients tested to carvone, supporting real-world allergy relevance even though positivity remained uncommon overall.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedJECFA's l-carvone flavoring specification lists the isolated material separately from d-carvone and describes the odor as spearmint-like.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Patch-test literature indicates carvone can cause allergic contact dermatitis in a subset of exposed people.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
No direct public citation is attached to this entry.
Most isolated-compound efficacy-style literature for carvone remains preclinical, so archive copy should avoid therapeutic framing.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
LimoneneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Limonene report →How the effects were investigated
TRPV1 agonism
A cell and neuron study reported that (-)-carvone increased intracellular calcium in dorsal root ganglion neurons and recombinant human TRPV1-expressing HEK293 cells, supporting TRPV1 activation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
oxidative and reductive human metabolism
Human metabolism work found l-carvone is converted mainly to dihydrocarvonic acid, carvonic acid, and uroterpenolone, with minor reduction to carveol and dihydrocarveol.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Most isolated l-carvone bioactivity literature remains preclinical or is mixed with generic carvone data rather than clearly separated enantiomer-specific human evidence.
- A constituent-specific modern dermal-use threshold for neat l-carvone was not verified in this pass.
- Some regulatory and safety literature still discusses parent carvone broadly, so enantiomer-specific interpretation requires care.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.